Hims & Hers Health, Inc. $HIMS Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. lowered its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 34.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,697 shares of the company’s stock after selling 17,357 shares during the period. Pacer Advisors Inc.’s holdings in Hims & Hers Health were worth $679,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of HIMS. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health during the third quarter worth approximately $28,000. Silicon Valley Capital Partners acquired a new stake in Hims & Hers Health in the third quarter valued at $48,000. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health during the 4th quarter valued at $28,000. Bogart Wealth LLC boosted its stake in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Revenue reached approximately $753.2 million, up 38.2% year over year and ahead of the roughly $698.9 million analyst consensus. The company cited strong subscriber growth and broader personalized healthcare offerings as key drivers. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, above the approximately $3.0 billion consensus. It also issued third-quarter revenue guidance of $880 million-$900 million, above expectations of $845.9 million. Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss
• Neutral Sentiment: The company said nearly 3 million people rely on its platform, reinforcing the importance of subscriber growth to its long-term expansion strategy. Hims & Hers Health Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Hims & Hers reported a quarterly loss instead of the expected smaller loss, compared with a profit in the prior-year quarter. The earnings miss highlighted continued pressure on margins and profitability despite rapid sales growth. Hims & Hers Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or fiduciary-duty breaches. These announcements do not establish wrongdoing but add legal and headline risk for shareholders. Kaplan Fox Investigation Announcement

Hims & Hers Health Trading Up 0.7%

NYSE:HIMS opened at $31.81 on Tuesday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $65.30. The firm has a market capitalization of $7.36 billion, a P/E ratio of -353.44, a P/E/G ratio of 88.90 and a beta of 2.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The business has a 50 day simple moving average of $31.94 and a 200 day simple moving average of $26.07.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.20 earnings per share. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Analyst Upgrades and Downgrades

HIMS has been the subject of several research analyst reports. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Barclays increased their price target on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 17th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Bank of America upped their price objective on Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research note on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $31.43.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 18,197 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91. Following the completion of the transaction, the chief financial officer owned 284,321 shares in the company, valued at approximately $9,675,443.63. This represents a 6.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. The trade was a 11.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 83,126 shares of company stock valued at $2,711,339. Corporate insiders own 11.76% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.